Oria Meds Tirzepatide Review: $369 a Month, Priced at Step Three (2026)

Oria Meds charges $369 a month for its compounded tirzepatide injection with B12, dosed at 2.5 mg weekly and billed monthly. It appears at step three of the intake, after a name, an email address, a phone number and a shipping address have been handed over. A first month is offered at $129, and $369 is the figure that renews.¹

What $369 buys and when you see it

The month-to-month plan ships every month and covers free expedited shipping, a home injection kit, dose increases at no charge and unlimited messaging. Committing longer lowers it, to $316 a month across three months and $299 a month across six, both shipped quarterly. Nothing is charged unless a provider writes the prescription.

The molecule arrives after your address

Neither semaglutide nor tirzepatide is named anywhere on the public site. The homepage sells a compounded GLP-1 and a compounded dual GIP/GLP-1, and the molecules first surface at step two of the intake, on a treatment screen reached after contact details and a full shipping address. Twenty-seven screens stand between the homepage and that first price, and our guide to tirzepatide against semaglutide is the comparison the site withholds until then.

Two floors that no plan matches

The homepage advertises Starting at $149 for the GLP-1 and Starting at $249 for the dual agonist, and neither figure appeared anywhere in the intake in either of the two states tested. The plan menu's own header rules out dose as the explanation, promising the same price at all dosage levels. The semaglutide ladder then runs backwards, with the one-month plan at $199 and both the three- and six-month plans at $209, so committing longer costs $10 more each month.

The brand-vs-compounded question

What Oria dispenses is compounded tirzepatide with B12, a pharmacy preparation rather than an FDA-approved finished product. Our guide to whether compounded tirzepatide is still legal in 2026 covers the ground that distinction now sits on.

How the care model holds up

The pharmacy is named properly: PerfectRx in Flower Mound, Texas, with a street address, a phone number and a website that resolves. The provider network is named as WizDoc, and the shipping selector covers 50 states, the District of Columbia and Puerto Rico. What is missing is the company itself, because no legal entity, no governing law, no clinician name and no NPI is published anywhere on the site. Two scarcity counters also run on consecutive screens, one reserving a single remaining discount and the next reporting 24 left, and review turnaround is 24 hours in the intake against 48 at checkout. Medication is not refundable once dispensed, including unopened vials.

Does the drug work? (Separate from the provider)

Price, disclosure and oversight are the seller's business; the molecule answers for itself in trial data. Tirzepatide's is strong, at roughly 15% to 21% of body weight over 72 weeks in SURMOUNT-1², and ahead of semaglutide where the two were compared in SURMOUNT-5³. Both trials used the branded drug at approved doses, which is not what arrives in this box.

The honest verdict

Oria Meds prices its tirzepatide clearly once you reach the plan menu, and everything before that menu is built to keep you walking. A named pharmacy with a full address is a real disclosure, and it sits beside no company name at all. RENN Health inverts that, naming six pharmacies and two prescribing physicians by NPI while publishing one price with no billing cycle attached. VevaRX shares the headline problem instead, printing an equivalent of $149 a month beside a $467 three-month charge that does not divide that way. The ranked best tirzepatide providers list shows where all three land.